Mohit Narang, MD, explains why he switches patients with chronic lymphocytic leukemia (CLL) to the second-generation Bruton tyrosine kinase inhibitor. Oncologists are increasingly opting for ...

Ibrutinib is associated with a higher AF risk compared to second-generation BTKis like acalabrutinib and zanubrutinib. The scoring system identifies low glomerular filtration rate, elevated ...